A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Riluzole (Primary) ; Sorafenib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 03 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
- 01 May 2017 Status changed from recruiting to active, no longer recruiting.